Constantinos Zamboglou

List of Publications by Year
in descending order

57 papers	1,332 citations	361413 20 h-index	377865 34 g-index
61 all docs	61 docs citations	61 times ranked	1379 citing authors

#	Article	IF	Citations
1	Editorial: Exploring the Potential of PSMA-PET Imaging on Personalized Prostate Cancer Treatment. Frontiers in Oncology, 2022, 12, 832747.	2.8	2
2	Implementation of PSMA-PET in focal dose-escalated radiotherapy of primary prostate cancer patients: Results of a planned safety analysis of a phase II trial.. Journal of Clinical Oncology, 2022, 40, 260-260.	1.6	0
3	Re: Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study. European Urology, 2022, , .	1.9	0
4	Explainable AI for CNN-based prostate tumor segmentation in multi-parametric MRI correlated to whole mount histopathology. Radiation Oncology, 2022, 17, 65.	2.7	20
5	PSMA-PET- and MRI-Based Focal Dose Escalated Radiation Therapy of Primary Prostate Cancer: Planned Safety Analysis of a Nonrandomized 2-Armed Phase 2 Trial (ARO2020-01). International Journal of Radiation Oncology Biology Physics, 2022, 113, 1025-1035.	0.8	12
6	Intraprostatic Tumor Segmentation on PSMA PET Images in Patients with Primary Prostate Cancer with a Convolutional Neural Network. Journal of Nuclear Medicine, 2021, 62, 823-828.	5.0	32
7	Development and validation of a novel prognostic score for elderly head-and-neck cancer patients undergoing radiotherapy or chemoradiation. Radiotherapy and Oncology, 2021, 154, 276-282.	0.6	19
8	Uncovering the invisibleâ€"prevalence, characteristics, and radiomics featureâ€“based detection of visually undetectable intraprostatic tumor lesions in 68GaPSMA-11 PET images of patients with primary prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1987-1997.	6.4	37
9	Radiomics in prostate cancer imaging for a personalized treatment approach - current aspects of methodology and a systematic review on validated studies. Theranostics, 2021, 11, 8027-8042.	10.0	39
10	Stereotactic Body Radiotherapy for High-Risk Prostate Cancer: A Systematic Review. Cancers, 2021, 13, 759.	3.7	18
11	Treatment outcomes of elderly salivary gland cancer patients undergoing radiotherapy â€“ Results from a large multicenter analysis. Radiotherapy and Oncology, 2021, 156, 266-274.	0.6	7
12	The impact of the co-registration technique and analysis methodology in comparison studies between advanced imaging modalities and whole-mount-histology reference in primary prostate cancer. Scientific Reports, 2021, 11, 5836.	3.3	20
13	Long-term Clinical Outcomes of Repeat Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: A Case Series. European Urology Focus, 2021, , .	3.1	3
14	Intraoperative radiotherapy boost as part of breast-conservation therapy for breast cancer: a single-institution retrospective analysis. Strahlentherapie Und Onkologie, 2021, 197, 812-819.	2.0	11
15	Radiotherapy in nodal oligorecurrent prostate cancer. Strahlentherapie Und Onkologie, 2021, 197, 575-580.	2.0	11
16	Combining 68Ga-PSMA-PET/CT-Directed and Elective Radiation Therapy Improves Outcome in Oligorecurrent Prostate Cancer: A Retrospective Multicenter Study. Frontiers in Oncology, 2021, 11, 640467.	2.8	11
17	Influence of Urethra Sparing on Tumor Control Probability and Normal Tissue Complication Probability in Focal Dose Escalated Hypofractionated Radiotherapy: A Planning Study Based on Histopathology Reference. Frontiers in Oncology, 2021, 11, 652678.	2.8	12
18	The Impact of Imaging Advances on Prostate Cancer Management: Many Unanswered Questions Remain. Practical Radiation Oncology, 2021, 11, 212-214.	2.1	0

#	Article	IF	Citations
19	Immunohistochemistry-based hypoxia-immune prognostic classifier for head-and-neck cancer patients undergoing chemoradiation â€“ Post-hoc analysis from a prospective imaging trial. Radiotherapy and Oncology, 2021, 159, 75-81.	0.6	8
20	Value of PET imaging for radiation therapy. Nuklearmedizin - NuclearMedicine, 2021, 60, 326-343.	0.7	2
21	Value of PET imaging for radiation therapy. Strahlentherapie Und Onkologie, 2021, 197, 1-23.	2.0	16
22	Innovative radiation oncology TogetherÂâ€“ Precise,ÂPersonalized,ÂHuman. Strahlentherapie Und Onkologie, 2021, 197, 1043-1048.	2.0	7
23	A Multi-Institutional Analysis of Prostate Cancer Patients With or Without 68Ga-PSMA PET/CT Prior to Salvage Radiotherapy of the Prostatic Fossa. Frontiers in Oncology, 2021, 11, 723536.	2.8	5
24	PSMA-PET/MRI-Based Focal Dose Escalation in Patients with Primary Prostate Cancer Treated with Stereotactic Body Radiation Therapy (HypoFocal-SBRT): Study Protocol of a Randomized, Multicentric Phase III Trial. Cancers, 2021, 13, 5795.	3.7	19
25	Changes in Blood Biomarkers of Angiogenesis and Immune Modulation after Radiation Therapy and Their Association with Outcomes in Thoracic Malignancies. Cancers, 2021, 13, 5725.	3.7	5
26	Outcome After 68Ga-PSMA-11 versus Choline PET-Based Salvage Radiotherapy in Patients with Biochemical Recurrence of Prostate Cancer: A Matched-Pair Analysis. Cancers, 2020, 12, 3395.	3.7	7
27	Isotropic Expansion of the Intraprostatic Gross Tumor Volume of Primary Prostate Cancer Patients Defined in MRIâ€"A Correlation Study With Whole Mount Histopathological Information as Reference. Frontiers in Oncology, 2020, 10, 596756.	2.8	5
28	Immunohistochemistry and Radiomic Features for Survival Prediction in Small Cell Lung Cancer. Frontiers in Oncology, 2020, 10, 1161.	2.8	14
29	Prostate cancer tumour control probability modelling for external beam radiotherapy based on multi-parametric MRI-GTV definition. Radiation Oncology, 2020, 15, 242.	2.7	7
30	Comparison of Manual and Semi-Automatic [18F]PSMA-1007 PET Based Contouring Techniques for Intraprostatic Tumor Delineation in Patients With Primary Prostate Cancer and Validation With Histopathology as Standard of Reference. Frontiers in Oncology, 2020, 10, 600690.	2.8	23
31	Impact of a low FODMAP diet on the amount of rectal gas and rectal volume during radiotherapy in patients with prostate cancer â€“ a prospective pilot study. Radiation Oncology, 2020, 15, 27.	2.7	7
32	Intraindividual comparison between 68Ga-PSMA-PET/CT and mpMRI for intraprostatic tumor delineation in patients with primary prostate cancer: a retrospective analysis in 101 patients. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2796-2803.	6.4	27
33	Radiotherapeutic management of cervical lymph node metastases from an unknown primary site â€“ experiences from a large cohort treated with modern radiation techniques. Radiation Oncology, 2020, 15, 80.	2.7	7
34	The value of moderate dose escalation for re-irradiation of recurrent or second primary head-and-neck cancer. Radiation Oncology, 2020, 15, 81.	2.7	21
35	Voxel-based comparison of [68Ga]Ga-RM2-PET/CT and [68Ga]Ga-PSMA-11-PET/CT with histopathology for diagnosis of primary prostate cancer. EJNMMI Research, 2020, 10, 62.	2.5	23
36	Predicting Biochemical Failure in Irradiated Patients With Prostate Cancer by Tumour Volume Measured by Multiparametric MRI. In Vivo, 2020, 34, 3473-3481.	1.3	0

#	Article	IF	Citations
37	Outcome After PSMA PET/CTâ€“Based Salvage Radiotherapy in Patients with Biochemical Recurrence After Radical Prostatectomy: A 2-Institution Retrospective Analysis. Journal of Nuclear Medicine, 2019, 60, 227-233.	5.0	61
38	Dosimetric Impact of Interfractional Variations in Prostate Cancer Radiotherapyâ€”Implications for Imaging Frequency and Treatment Adaptation. Frontiers in Oncology, 2019, 9, 940.	2.8	20
39	Validation of different PSMA-PET/CT-based contouring techniques for intraprostatic tumor definition using histopathology as standard of reference. Radiotherapy and Oncology, 2019, 141, 208-213.	0.6	42
40	[68Ga-]PSMA-11 PET/CT and multiparametric MRI for gross tumor volume delineation in a slice by slice analysis with whole mount histopathology as a reference standard â€“ Implications for focal radiotherapy planning in primary prostate cancer. Radiotherapy and Oncology, 2019, 141, 214-219.	0.6	83
41	Radiomic features from PSMA PET for non-invasive intraprostatic tumor discrimination and characterization in patients with intermediate- and high-risk prostate cancer - a comparison study with histology reference. Theranostics, 2019, 9, 2595-2605.	10.0	105
42	Dosimetric Impact of Interfractional Variations for Post-prostatectomy Radiotherapy to the Prostatic Fossaâ€”Relevance for the Frequency of Position Verification Imaging and Treatment Adaptation. Frontiers in Oncology, 2019, 9, 1191.	2.8	5
43	Impact of ⁶⁸Ga-PSMA PET/CT on the Radiotherapeutic Approach to Prostate Cancer in Comparison to CT: A Retrospective Analysis. Journal of Nuclear Medicine, 2019, 60, 963-970.	5.0	44
44	Influence of inhomogeneous radiosensitivity distributions and intrafractional organ movement on the tumour control probability of focused IMRT in prostate cancer. Radiotherapy and Oncology, 2018, 127, 62-67.	0.6	4
45	Biological imaging for individualized therapy in radiation oncology: part II medical and clinical aspects. Future Oncology, 2018, 14, 751-769.	2.4	7
46	Multimodal imaging for radiation therapy planning in patients with primary prostate cancer. Physics and Imaging in Radiation Oncology, 2018, 8, 8-16.	2.9	8
47	PSMA-PET based radiotherapy: a review of initial experiences, survey on current practice and future perspectives. Radiation Oncology, 2018, 13, 90.	2.7	34
48	The dose distribution in dominant intraprostatic tumour lesions defined by multiparametric MRI and PSMA PET/CT correlates with the outcome in patients treated with primary radiation therapy for prostate cancer. Radiation Oncology, 2018, 13, 65.	2.7	26
49	Combined high dose rate brachytherapy and external beam radiotherapy for clinically localised prostate cancer. Radiotherapy and Oncology, 2018, 128, 301-307.	0.6	14
50	Focal dose escalation for prostate cancer using 68Ga-HBED-CC PSMA PET/CT and MRI: a planning study based on histology reference. Radiation Oncology, 2018, 13, 81.	2.7	53
51	Evaluation of intensity modulated radiation therapy dose painting for localized prostate cancer using 68 Ga-HBED-CC PSMA-PET/CT: A planning study based on histopathology reference. Radiotherapy and Oncology, 2017, 123, 472-477.	0.6	50
52	Comparison of ⁶⁸Ga-HBED-CC PSMA-PET/CT and multiparametric MRI for gross tumour volume detection in patients with primary prostate cancer based on slice by slice comparison with histopathology. Theranostics, 2017, 7, 228-237.	10.0	135
53	Single fraction multimodal image guided focal salvage high-dose-rate brachytherapy for recurrent prostate cancer. Journal of Contemporary Brachytherapy, 2016, 3, 241-248.	0.9	22
54	⁶⁸Ga-HBED-CC-PSMA PET/CT Versus Histopathology In Primary Localized Prostate Cancer: A Voxel-Wise Comparison. Theranostics, 2016, 6, 1619-1628.	10.0	89

#	Article	IF	Citations
55	MRI versus 68Ga-PSMA PET/CT for gross tumour volume delineation in radiation treatment planning of primary prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 889-897.	6.4	68
56	Radiotherapy for SMAD4-negative musculoskeletal lesions from pancreatic cancer. Strahlentherapie Und Onkologie, 2015, 191, 67-72.	2.0	0
57	Intraindividual Comparison Between [18F] PSMA-1007 PET/CT and Multiparametric MRI for Radiotherapy Planning in Primary Prostate Cancer Patients. Frontiers in Oncology, 0, 12, .	2.8	2